MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-07-2025
Fulgent Genetics DPO Ratio 2011-2026 | FLGT
Annual DPO Ratio Fulgent Genetics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 34.9 | 38 | 31.6 | 39.8 | 57 | 40.9 | 44.8 | 89.2 | 150 | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 150 | 31.6 | 58.4 |
Quarterly DPO Ratio Fulgent Genetics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 34.7 | 35.8 | 37 | - | 40.2 | 40.5 | 37.6 | - | 37 | 41.2 | 43.5 | - | 11.1 | 18 | 25.9 | 33.3 | 41.6 | 41 | 27.1 | 46.7 | 92 | 313 | 316 | 39.7 | 37.1 | 39.9 | 44.5 | 43.3 | 45.9 | 47.1 | 56 | 74.9 | 84 | 101 | 119 | 135 | 117 | 178 | 107 | 10.5 | 15.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 316 | 10.5 | 68.7 |
DPO Ratio of other stocks in the Diagnostics research industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
21.3 | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
120 | - | -6.23 % | $ 30.6 M |  Germany |
 |
Accelerate Diagnostics
AXDX
|
125 | - | -61.36 % | $ 2.46 M |  USA |
 |
Burning Rock Biotech Limited
BNR
|
125 | $ 20.15 | -2.3 % | $ 217 M |  China |
 |
Co-Diagnostics
CODX
|
106 | $ 0.17 | -6.7 % | $ 4.99 M | USA |
 |
Biocept
BIOC
|
56.3 | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
52.5 | - | 0.22 % | $ 16.8 M | USA |
 |
Danaher Corporation
DHR
|
66.4 | $ 228.92 | -0.76 % | $ 167 B | USA |
 |
BioNano Genomics
BNGO
|
104 | $ 1.53 | 2.0 % | $ 1.94 M | USA |
 |
DexCom
DXCM
|
70.4 | $ 66.37 | -1.03 % | $ 25.6 B | USA |
 |
Castle Biosciences
CSTL
|
52 | $ 38.9 | -1.04 % | $ 1.08 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
45.8 | - | - | $ 562 M |  Britain |
 |
DermTech
DMTK
|
47.4 | - | -11.32 % | $ 2.94 M | USA |
 |
DarioHealth Corp.
DRIO
|
43.9 | $ 11.38 | 6.36 % | $ 323 M |  Israel |
 |
Enzo Biochem
ENZ
|
52.3 | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
139 | $ 101.56 | -0.33 % | $ 18.8 B | USA |
 |
Global Cord Blood Corporation
CO
|
17.7 | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
61.4 | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
780 | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
43.5 | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
8.98 | - | - | $ 10.7 B | USA |
 |
CareDx, Inc
CDNA
|
44.2 | $ 18.84 | -1.21 % | $ 1.01 B | USA |
 |
IQVIA Holdings
IQV
|
126 | $ 225.41 | -1.0 % | $ 40.9 B | USA |
 |
Anixa Biosciences
ANIX
|
1.29 K | $ 3.12 | - | $ 99.5 K | USA |
 |
Heska Corporation
HSKA
|
39.7 | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
112 | - | -20.0 % | $ 1.06 M | USA |
 |
Guardant Health
GH
|
83.6 | $ 102.14 | 1.53 % | $ 12.5 B | USA |
 |
Aspira Women's Health
AWH
|
112 | - | -6.19 % | $ 10.5 M | USA |
 |
ENDRA Life Sciences
NDRA
|
1.65 K | $ 4.53 | -4.83 % | $ 2.43 M | USA |
 |
Myriad Genetics
MYGN
|
42 | $ 6.15 | -0.32 % | $ 557 M | USA |
 |
NeoGenomics
NEO
|
20.7 | $ 11.76 | -3.84 % | $ 1.49 B | USA |
 |
Illumina
ILMN
|
56.3 | $ 131.16 | -1.2 % | $ 20.9 B | USA |
 |
Charles River Laboratories International
CRL
|
24.5 | $ 199.48 | -1.24 % | $ 10.2 B | USA |
 |
National Research Corporation
NRC
|
10.1 | $ 18.77 | 0.64 % | $ 461 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
18.3 | $ 173.53 | -1.12 % | $ 19.3 B | USA |
 |
Motus GI Holdings
MOTS
|
1.72 | - | -34.28 % | $ 263 K | Israel |
 |
Laboratory Corporation of America Holdings
LH
|
33.1 | $ 250.88 | -0.87 % | $ 21 B | USA |
 |
ICON Public Limited Company
ICLR
|
6.52 | $ 182.22 | -0.43 % | $ 15 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
27 | $ 676.53 | -0.85 % | $ 55.8 B | USA |
 |
Lantheus Holdings
LNTH
|
25.3 | $ 66.55 | -0.91 % | $ 4.61 B | USA |
 |
Mettler-Toledo International
MTD
|
53.4 | $ 1 394.19 | -1.42 % | $ 29.6 B |  Schweiz |
 |
Precipio
PRPO
|
53 | $ 22.98 | -1.84 % | $ 29.8 M | USA |
 |
Agilent Technologies
A
|
50.1 | $ 136.07 | -1.13 % | $ 41.4 B | USA |
 |
Personalis
PSNL
|
67.3 | $ 7.96 | -0.13 % | $ 472 M | USA |
 |
Biomerica
BMRA
|
32.4 | $ 2.52 | 2.86 % | $ 5.79 M | USA |
 |
Bioventus
BVS
|
59.2 | $ 7.44 | -0.13 % | $ 466 M | USA |